Phase 2 efficacy trial of Respiratory Syncytial Virus (RSV) F Vaccine in older adults.
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2017
Price : $35 *
At a glance
- Drugs RSV F protein vaccine-Novavax (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacodynamics; Therapeutic Use
- 28 Jul 2017 New trial record
- 24 Jul 2017 According to a Novavax media release, company anticipates initiating this trial in 2018.